FORBEST ® - Flunisolide

FORBEST ® is a Flunisolide based drug

THERAPEUTIC GROUP: Drugs for obstructive airway disorders

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications FORBEST ® - Flunisolide

FORBEST ® is indicated in the treatment of allergic respiratory diseases such as bronchial asthma, chronic asthma-like bronchitis and chronic or seasonal allergic rhinitis.

Action mechanism FORBEST ® - Flunisolide

Flunisolide, the active ingredient of the medicinal specialty FORBEST ®, is a very active corticosteroid for topical administration, successfully used in the treatment and prevention of allergic obstructive airway symptoms.

Taken in the form of a nasal spray or nebulization solution, it performs its therapeutic action locally in just a few minutes, determining, like other corticosteroids, a significant reduction in the inflammatory degree of the respiratory mucosa through the inhibition of inflammatory cytokine synthesis and mediators of inflammation.

All this is realized in the reduced degree of phlogistic activation of the mucosa, in the inhibition of the recruitment mechanisms of phlogosis cells and of circulating basophils, in the decongestant action of the upper respiratory tract mucosa, in the control of mucus secretion and therefore in a clear improvement of the complained symptomatology.

The share of drug absorbed through these inflamed mucous membranes is metabolised to the liver level and immediately catabolized into a pharmacologically inactive metabolite.

Studies carried out and clinical efficacy

TOPIC THERAPY VS SYSTEMIC THERAPY

Pediatr Pulmonol. 2013 Aug 8. doi: 10.1002 / ppul.22846. [Epub ahead of print]

Beckhaus AA, Riutort MC, Castro-Rodriguez JA.

Work demonstrating the absence of differences between the inhalation or systemic administration of corticosteroids for the treatment of asthma exacerbation, in terms of therapeutic efficacy.

However, it is clear, however, that topical administration could save some of the side effects classically associated with systemic therapy.

FLUNISOLIDE AND GROWTH

Ann Allergy Asthma Immunol. 2011 Oct; 107 (4): 323-9. doi: 10.1016 / j.anai.2011.07.017. Epub 2011 Sep 3.

A double-blind clinical study that demonstrates how local administration of Flunisolide, even if prolonged for prolonged periods, does not suppress the growth or correct maturation of the bone in very young patients.

FLUNISOLIDE AND NON-ALLERGIC RHINITIS

Int J Immunopathol Pharmacol. 2011 Apr-Jun; 24 (2): 401-9.

Work that seeks to extend the potential clinical applications of Flunisolide demonstrating its clinical efficacy even in cases of non-allergic rhinitis characterized by inflammation and hyperactivity of the nasal mucosa.

Method of use and dosage

FORBEST ®

Nebulized solution of 0.5 - 1 - 2 mg of Flunisolide per ml of solution.

The definition of the dosage and of the therapeutic scheme to be followed during the treatment is the responsibility of the doctor after having carefully evaluated the patient's state of health and the severity of his clinical picture.

In general, in adults it is recommended to inhale 1 mg of Fluticasone twice a day.

FORBEST ® warnings - Flunisolide

The administration of FORBEST ® should necessarily be preceded by a careful medical examination aimed at clarifying the etiological origin of the complained clinical picture and therefore the possible prescriptive appropriateness.

Corticosteroid therapy, even if inhaled, poses some important precautions to consider, such as:

avoid prolonged administration, potentially responsible for hypersensitivity reactions and various symptoms;
to consider the greater susceptibility of the individual to pathologies of infectious origin;
periodically check adrenal function;
avoid exceeding recommended doses and times;
combine therapy with vasoconstrictors in the event that there is an imposing congestion of the mucous membranes, such as to make breathing difficult.

It is also worth mentioning the inadequacy of Flunisolide in the treatment of the acute asthmatic phase.

The use of Corticosteroids, without clinical necessity, is prohibited in and out of the race.

It is recommended to keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

The absence of studies able to fully characterize the safety profile of Flunisolide for fetal and infant health, extends the aforementioned contraindications to the use of FORBEST ® also to pregnancy and the subsequent breastfeeding period.

Interactions

Pharmacological interactions worthy of note are not known at the moment, although the simultaneous intake of inhibitors or inducers of the cytochromial system would be able to alter the pharmacokinetic characteristics of the possible quota of Flunisolide absorbed.

Contraindications FORBEST ® - Flunisolide

The use of FORBEST ® is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients, in patients suffering from active or quiescent viral and tuberculosis infections and in pregnant and lactating women.

Undesirable effects - Side effects

The therapy with inhaled corticosteroids such as Flunisolide, could determine, especially in particularly sensitive patients, the onset of local adverse reactions such as nasal irritation, epistaxis, rhinorrhea, sore throat, hoarseness and irritation of the oral cavity.

Fortunately the systemic adverse reactions typical of corticosteroids worthy of clinical note are rarer.